Moxifloxacin Yinqiaosan Modified Joint Hospital-acquired Pneumonia In The Treatment Of Clinical Value

Purpose:To select some of Respiratory Medicine, Hubei Province, Chinese medicine hospital in-patients, observed and compared the treatment group and control group patients, of moxifloxacin combined Yinqiaosan Treatment of Modified Hospital acquired pneumonia (HAP) of clinical value.Method:Hubei Province Chinese Medicine Hospital suffering from hospital-acquired pneumonia in 35 patients, diagnosis of cough medicine, Asthma. Selected from patients meeting the following requirements: None combined with other underlying diseases, non-pregnant or lactating women, no to quinolones and macrolides history of drug allergy.31 patients evaluable patients. Randomly divided into treatment group and control group, treatment group 15 cases,16 cases of the control group. Routine treatment control group. Treatment and control groups in gender, age, body weight, past medical history, disease, electrocardiogram, examination results, and sputum culture and so on, no significant difference between comparable.Symptomatic treatment group given routine treatment and moxifloxacin tablets (thanks to complex music, the German Bayer Corporation Bayer Pharmaceuticals production, specifications 400mg/tablet. Oral,400mg/ times,1 time/day.), Plus or minus side Yinqiaosan (Forsythia, Silver Flower, bitter Campanulaceae, mint, bamboo leaves, raw licorice, Schizonepeta spike, SSP, Arctium. Clinical Modified:hot clip is poor, mediastinoscopy full nausea, plus Agastache rugosa, turmeric; Tianjin injury very thirsty, plus pollen; heat rather than toxicity, entry swollen sore throat, Canadian participation; lung negative, cough and even, Almond; heat gradually into the years, plus fine habitat, Ophiopogon japonicus; further understand, plus Zhimu, skullcap). Routine treatment control group (symptomatic treatment, then use antibiotics according to sputum culture).Efficacy Evaluation:According to the Ministry of Health issued "Guidance on Clinical Investigation of antibiotics standards", based on clinical symptoms, signs, laboratory tests, and bacteriology comprehensive assessment to determine the clinical efficacy, according to recover markedly, progress and assessment invalid 4. Results:Treatment and control groups in age, gender, symptom score before treatment, the infection had no significant difference between the types of bacteria, comparable.After treatment, the treatment group and control group in symptom score after treatment, the infection rate of bacterial clearance were statistically significant, and the treatment of the bacterial eradication rate was 90.6%> 71.0% in control group, and therefore may explain the clinical treatment group better treatment than the control group.After treatment, the treatment group and control group in efficacy levels, the total effective rate was not statistically significant, but the efficiency of the treatment group [total effective/total] 68.8%> control group was 48.4%.After treatment, the treatment group and control group, there were two cases of minor symptoms of adverse reactions, and no significant difference.Conclusion:Can be considered:joint Yinqiaosan moxifloxacin plus or minus side in the clinical treatment of hospital-acquired pneumonia (HAP) have a more reliable value.